Home / Business and Economy / Eli Lilly Stock Nears Split Threshold Amidst Record Growth
Eli Lilly Stock Nears Split Threshold Amidst Record Growth
4 Aug
Summary
- Eli Lilly's stock price has surged over 285% since 2022.
- The company surpassed $1 trillion in valuation, a pharma first.
- High share price fuels speculation of a potential stock split.
Wall Street's strong interest in weight-loss drug stocks has significantly boosted Eli Lilly & Co.'s share price, driving it consistently above $1,000. Since 2022, Lilly's stock has surged by an impressive 285%.
This remarkable performance is attributed to the success of its GLP-1 drugs, Mounjaro for diabetes and Zepbound for obesity. These approvals enabled Lilly to become the first pharmaceutical company to achieve a $1 trillion valuation, positioning it among the top S&P 500 companies.
The company's high share price has sparked discussions about a potential stock split. Such a move could make shares more accessible to a broader range of investors, potentially attracting new shareholders.
While Eli Lilly has not announced any plans for a stock split, analysts view the prospect positively, suggesting it could further enhance the company's appeal and investor base.
